Delving into the Latest Updates on Enriched hematopoetic stem cell infusion(University of Louisville) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCongenital Disorders+ [4]

Active Indication-

Inactive Indication

AdrenoleukodystrophyAlpha-MannosidosisAlpha-Thalassemia+ [15]

Originator Organization

University of Louisville

Active Organization-

Inactive Organization

Talaris Therapeutics, Inc.

University of Louisville

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

To study the effect of the stem cells therapy autologous mononuclear from the bone marrow, autologous progenitor endothelial CD133 cells from the bone marrow and autologous mesenchymal stem cells from adipose tissue on the inflammatory cytokines, the resistance to insulin and the decrease of the needs of insulin, besides evaluates the safety, viability and efficiency of the intra-arterial infusion of stem cells in diabetic patients type 2 with CLI.

Start Date01 Sep 2011

Sponsor / Collaborator-

NCT01419704

/ WithdrawnPhase 1/2

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.

Start Date01 May 2011

Sponsor / Collaborator

Talaris Therapeutics, Inc.

[+1]

NCT01372228

/ TerminatedPhase 1/2

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

The goal of this research study is to establish chimerism and avoid graft-versus-host-disease (GVHD) in patients with inherited metabolic disorders.

Start Date01 Apr 2011

Sponsor / Collaborator

Talaris Therapeutics, Inc.

[+1]

100 Clinical Results associated with Enriched hematopoetic stem cell infusion(University of Louisville)

Login to view more data

100 Translational Medicine associated with Enriched hematopoetic stem cell infusion(University of Louisville)

Login to view more data

100 Patents (Medical) associated with Enriched hematopoetic stem cell infusion(University of Louisville)

Login to view more data

100 Deals associated with Enriched hematopoetic stem cell infusion(University of Louisville)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal transplant rejection	Phase 2	-	Talaris Therapeutics, Inc.	01 May 2012
Alpha-Thalassemia	Phase 2	United States	Talaris Therapeutics, Inc.	01 May 2011
Anemia, Diamond-Blackfan	Phase 2	United States	Talaris Therapeutics, Inc.	01 May 2011
Beta-Thalassemia	Phase 2	United States	Talaris Therapeutics, Inc.	01 May 2011
Adrenoleukodystrophy	Phase 2	United States	Talaris Therapeutics, Inc.	01 Apr 2011
Alpha-Mannosidosis	Phase 2	United States	Talaris Therapeutics, Inc.	01 Apr 2011
Leukodystrophy, Globoid Cell	Phase 2	United States	Talaris Therapeutics, Inc.	01 Apr 2011
Mucopolysaccharidosis I	Phase 2	United States	Talaris Therapeutics, Inc.	01 Apr 2011
Mucopolysaccharidosis II	Phase 2	United States	Talaris Therapeutics, Inc.	01 Apr 2011
Mucopolysaccharidosis III	Phase 2	United States	Talaris Therapeutics, Inc.	01 Apr 2011